Literature DB >> 23659643

Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab.

Cyril Gitiaux1, Pauline Krug, David Grevent, Manoelle Kossorotoff, Sarah Poncet, Monika Eisermann, Mehdi Oualha, Nathalie Boddaert, Remi Salomon, Isabelle Desguerre.   

Abstract

AIM: The aim of this study was to describe the magnetic resonance imaging (MRI) findings and the neurological and neuropsychological outcomes in paediatric, diarrhoea-associated haemolytic-uraemic syndrome (D+HUS) with central nervous system impairment treated with eculizumab, a monoclonal antibody.
METHOD: The 14-month single-centre prospective study included seven children (three males, four females; age range 16 mo-7 y 8 mo; median age 3 y 7 mo) with typical D+HUS and acute neurological impairment. In the acute phase of the disease, neurological assessment and brain magnetic resonance imaging (MRI), including measurement of the apparent diffusion coefficient (ADC), were performed, and neuropsychological evaluation and brain MRI were also carried out 6 months after disease onset.
RESULTS: In the acute phase, basal ganglia and white matter abnormalities with ADC restriction were a common and reversible MRI finding. In all the surviving patients (5/7), follow-up MRI after 6 months was normal, indicating reversible lesions. Clinical and neuropsychological evaluations after 6 months were also normal.
INTERPRETATION: This specific brain MRI pattern consisting of an ADC decrease in basal ganglia and white matter without major T2/fluid-attenuated inversion recovery (FLAIR) injury may be a key finding in the acute phase of the disease in favour of a vasculitis hypothesis. These reversible lesions were associated with a good neurological outcome. These results call for further evaluation of the potential role of eculizumab in the choice of treatment for severe D+HUS, particularly in the case of early neurological signs.
© 2013 Mac Keith Press.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23659643     DOI: 10.1111/dmcn.12161

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  14 in total

1.  Macrovascular involvement in a child with atypical hemolytic uremic syndrome.

Authors:  Karolis Ažukaitis; Chantal Loirat; Michal Malina; Irina Adomaitienė; Augustina Jankauskienė
Journal:  Pediatr Nephrol       Date:  2013-12-19       Impact factor: 3.714

2.  Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.

Authors:  Lucas Percheron; Raluca Gramada; Stéphanie Tellier; Remi Salomon; Jérôme Harambat; Brigitte Llanas; Marc Fila; Emma Allain-Launay; Anne-Laure Lapeyraque; Valerie Leroy; Anne-Laure Adra; Etienne Bérard; Guylhène Bourdat-Michel; Hassid Chehade; Philippe Eckart; Elodie Merieau; Christine Piètrement; Anne-Laure Sellier-Leclerc; Véronique Frémeaux-Bacchi; Chloe Dimeglio; Arnaud Garnier
Journal:  Pediatr Nephrol       Date:  2018-03-23       Impact factor: 3.714

Review 3.  Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence.

Authors:  Werner Keenswijk; Ann Raes; Johan Vande Walle
Journal:  Eur J Pediatr       Date:  2017-12-29       Impact factor: 3.183

4.  Eculizumab Use in a Temporarily Dialysis-Dependent Patient With Shiga Toxin-Producing Escherichia Coli Hemolytic Uremic Syndrome With Neurological Complications.

Authors:  Bo Weber; Dominic Chan; Sandy Hammer
Journal:  J Pediatr Pharmacol Ther       Date:  2021-12-22

5.  HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.

Authors:  Carla Galvez; Paola Krall; Alejandro Rojas; Jun Oh; Francisco Cano
Journal:  Pediatr Nephrol       Date:  2022-08-15       Impact factor: 3.651

6.  Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome.

Authors:  Angela Bauer; Sebastian Loos; Carola Wehrmann; Dirk Horstmann; Frank Donnerstag; Johanna Lemke; Georg Hillebrand; Ulrike Löbel; Lars Pape; Dieter Haffner; Carola Bindt; Thurid Ahlenstiel; Anette Melk; Anja Lehnhardt; Markus J Kemper; Jun Oh; Hans Hartmann
Journal:  Pediatr Nephrol       Date:  2014-03-25       Impact factor: 3.714

7.  A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.

Authors:  Paolo Giordano; Giuseppe Stefano Netti; Luisa Santangelo; Giuseppe Castellano; Vincenza Carbone; Diletta Domenica Torres; Marida Martino; Michela Sesta; Franca Di Cuonzo; Maria Chiara Resta; Alberto Gaeta; Leonardo Milella; Maria Chironna; Cinzia Germinario; Gaia Scavia; Loreto Gesualdo; Mario Giordano
Journal:  Pediatr Nephrol       Date:  2018-10-25       Impact factor: 3.714

8.  Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.

Authors:  Lars Pape; Hans Hartmann; Franz Christoph Bange; Sebastian Suerbaum; Eva Bueltmann; Thurid Ahlenstiel-Grunow
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

9.  Hemolytic Uremic Syndrome Causing Multicystic Leukoencephalomalacia.

Authors:  Abdussamet Batur; Muhammed Alpaslan; Alpaslan Yavuz; Aydın Bora; Mehmet Deniz Bulut
Journal:  Pol J Radiol       Date:  2016-06-01

10.  Neurological Sequelae in Adults After E coli O104: H4 Infection-Induced Hemolytic-Uremic Syndrome.

Authors:  Ramona Schuppner; Justus Maehlmann; Meike Dirks; Hans Worthmann; Anita B Tryc; Kajetan Sandorski; Elisabeth Bahlmann; Jan T Kielstein; Anja M Giesemann; Heinrich Lanfermann; Karin Weissenborn
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.